Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
As the aging population in the US, UK and Europe increases, cases of multiple have increased as well, bring new therapies and questions about the future of care. This webinar provides a comprehensive look at the disease and treatments including the new launches that are transforming clinical practice, the relative value of multiple myeloma regimens, and the evolution of the multiple myeloma market.
Beginning with the current access levers used by payers and a comparison of US and five major European markets, you’ll learn the key factors in European payers’ assessment of multiple myeloma treatments, the significant changes we are seeing in the US oncology market, and why payers have begun imposing cost-control strategies such as ICER and other value frameworks to evaluate cost-effectiveness.
Datamonitor Healthcare: data analysis and insight
14 Nov 2022
Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.
Datamonitor Healthcare: data analysis and insight
By Dominique Fontanilla 14 Nov 2022
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
Topics Cancer
Datamonitor Healthcare: data analysis and insight
14 Nov 2022
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
Biomedtracker: see the drug development process through anal...
Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.
Datamonitor Healthcare: data analysis and insight, Biomedtra...
The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.
Topics Cancer
Datamonitor Healthcare: data analysis and insight
One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed.
Topics Drug Review Drug Pricing
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
